Format

Send to

Choose Destination
Crit Rev Eukaryot Gene Expr. 2018;28(4):373-384. doi: 10.1615/CritRevEukaryotGeneExpr.2018025121.

Interferon-Free Regimen for Hepatitis C: Insight and Management.

Author information

1
Department of Bioinformatics and Biotechnology, Government College University Faisalabad (GCUF), Pakistan.
2
Department of Bioinformatics & Biotechnology, Government College University, 38000 Faisalabad, Pakistan.

Abstract

The rapid development of direct-acting antiviral agents (DAA) for hepatitis C virus (HCV) therapy dramatically altered the treatment landscape of this disease. The DAA regimen is associated with various advantages including high sustained virological response (SVR) with minimum side effects and low pill load and specific inhibition of viral replication, which lowers dependence on the host cell. This regimen has substantially replaced conventional (interferon) therapy with high cure rates (> 90%) in most HCV populations. This review provides insight into clinical studies of NS3/4A protease inhibitors, NS5B viral polymerase inhibitor (nucleotide and non-nucleotide), and NS5A inhibitors, alone and in combination.

Supplemental Content

Full text links

Icon for BegellHouse Publisher, Inc.
Loading ...
Support Center